Challenges and Solutions for the Benefit Assessment of Tumor-Agnostic Therapies in Germany
Open Access
- 25 January 2023
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 26 (6), 854-864
- https://doi.org/10.1016/j.jval.2023.01.011
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- PCN94 CHALLENGES AND AN APPROACH TO PERFORMING COST-EFFECTIVENESS ANALYSES BASED ON SINGLE ARM BASKET TRIALS FOR PAN-TUMOR INDICATIONSValue in Health, 2019
- PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Value in Health, 2018
- Precision medicine becomes reality—tumor type‐agnostic therapyCancer Communications, 2018
- Tissue-Agnostic Drug DevelopmentAsco Educational Book, 2017
- Tissue-Agnostic Drug DevelopmentAsco Educational Book, 2017
- Simultaneous and Sequential Qualitative Mixed Method DesignsQualitative Inquiry, 2010
- Target-specific randomized discontinuation trial design: a novel approach in molecular therapeuticsInvestigational New Drugs, 2009
- Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groupsInternational Journal for Quality in Health Care, 2007
- When are randomised trials unnecessary? Picking signal from noiseBMJ, 2007
- The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJournal of Clinical Epidemiology, 1997